Zhejiang Tianyu Pharmaceutical Co.,Ltd. (SHE: 300702) has announced that its active pharmaceutical ingredient for brivaracetam has recently passed the review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
This pharmaceutical is indicated for the adjunctive treatment of partial-onset seizures, particularly for patients who show an inadequate response to other antiepileptic drugs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments